Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK

Hao,Zhenfeng; Qian,Jing; Yang,Jishi

doi:10.3892/ol.2014.2771

Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK

Authors:
- Zhenfeng Hao
- Jing Qian
- Jishi Yang
View Affiliations

Affiliations: Laboratory of Traditional Chinese Medicines, Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China, Department of Gynecology and Obstetrics, The Affiliated Taixing Hospital, Yangzhou University, Yangzhou, Jiangsu 225004, P.R. China
Published online on: December 5, 2014 https://doi.org/10.3892/ol.2014.2771
Pages: 629-633
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study identified that shikonin, a naphthoquinone extracted from the roots of Lithospermum erythrorhizon, inhibits the migration of ovarian cancer cells and induces their apoptosis by impairing the phosphorylation of two kinases, proto-oncogene tyrosine protein kinase Src (Src) and focal adhesion kinase (FAK). Ovarian carcinoma SKOV‑3 cells were treated with various concentrations of shikonin and analyzed for the effects on cell migration, invasion and apoptosis via Transwell assays and flow cytometry. In addition, the effects of shikonin administration on the expression and phosphorylation of Src and FAK in the SKOV‑3 cells were analyzed by western blotting. Shikonin appeared to induce apoptosis and decrease cell migration in the SKOV‑3 ovarian cells. Furthermore, the present study provides evidence that shikonin may exert these effects on human ovarian carcinoma cells via the inhibition of the protein tyrosine kinases, Src and FAK. Thus, shikonin should be considered for additional investigation as a candidate agent for the prevention and treatment of human ovarian cancer.

View Figures

View References

1	Ishida T and Sakaguchi I: Protection of human keratinocytes from UVB-induced inflammation using root extract of Lithospermum erythrorhizon. Biol Pharm Bull. 30:928–934. 2007. View Article : Google Scholar : PubMed/NCBI
2	Yeh CC, Kuo HM, Li TM, et al: Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24). In Vivo. 21:1011–1019. 2007.
3	Wu Z, Wu LJ, Tashiro S, et al: Phosphorylated extracellular signal-regulated kinase up-regulated p53 expression in shikonin-induced HeLa cell apoptosis. Chin Med J (Engl). 118:671–677. 2005.
4	Li W, Liu J, Jackson K, Shi R and Zhao Y: Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells. PloS One. 9:e940792014. View Article : Google Scholar : PubMed/NCBI
5	Jang SY, Jang EH, Jeong SY and Kim JH: Shikonin inhibits the growth of human prostate cancer cells via modulation of the androgen receptor. Int J Oncol. 44:1455–1460. 2014.PubMed/NCBI
6	Wang W, Dai M, Zhu C, et al: Synthesis and biological activity of novel shikonin analogues. Bioorg Med Chem Lett. 19:735–737. 2009. View Article : Google Scholar
7	Al-Obeidi FA and Lam KS: Development of inhibitors for protein tyrosine kinases. Oncogene. 19:5690–5701. 2000. View Article : Google Scholar : PubMed/NCBI
8	Hunter T: Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 80:225–236. 1995. View Article : Google Scholar : PubMed/NCBI
9	Wheeler DL, Iida M and Dunn EF: The role of Src in solid tumors. Oncologist. 14:667–678. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wiener JR, Windham TC, Estrella VC, et al: Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol. 88:73–79. 2003. View Article : Google Scholar
11	Parsons JT: Focal adhesion kinase: the first ten years. J Cell Sci. 116:1409–1416. 2003. View Article : Google Scholar : PubMed/NCBI
12	Westhoff MA, Serrels B, Fincham VJ, et al: SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol. 24:8113–8133. 2004. View Article : Google Scholar : PubMed/NCBI
13	Schlaepfer DD and Mitra SK: Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev. 14:92–101. 2004. View Article : Google Scholar : PubMed/NCBI
14	Peng X, Ueda H, Zhou H, et al: Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovasc Res. 64:421–430. 2004. View Article : Google Scholar : PubMed/NCBI
15	Judson PL, He X, Cance WG and Van Le L: Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer. 86:1551–1556. 1999. View Article : Google Scholar : PubMed/NCBI
16	Sankawa U, Ebizuka Y, Miyazaki T, Isomura Y and Otsuka H: Antitumor activity of shikonin and its derivatives. Chem Pharm Bull (Tokyo). 25:2392–2395. 1977. View Article : Google Scholar
17	Sankawa U, Otsuka H, Kataoka Y, Iitaka Y, Hoshi A and Kuretani K: Antitumor activity of shikonin, alkannin and their derivatives. II X-ray analysis of cyclo-alkannin leucoacetate, tautomerism of alkannin and cyclo-alkannin and antitumor activity of alkannin derivatives. Chem Pharm Bull (Tokyo). 29:116–122. 1981. View Article : Google Scholar
18	Yang H, Zhou P, Huang H, et al: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer. 124:2450–2459. 2009. View Article : Google Scholar : PubMed/NCBI
19	Lee HJ, Lee HJ, Magesh V, Nam D, et al: Shikonin, acetylshikonin and isobutyroylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice. Yakugaku Zasshi. 128:1681–1688. 2008. View Article : Google Scholar : PubMed/NCBI
20	Wu Z, Wu L, Li L, Tashiro S, Onodera S and Ikejima T: p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci. 94:166–176. 2004. View Article : Google Scholar : PubMed/NCBI
21	Han W, Li L, Qiu S, et al: Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther. 6:1641–1649. 2007. View Article : Google Scholar : PubMed/NCBI
22	Hsu PC, Huang YT, Tsai ML, Wang YJ, Lin JK and Pan MH: Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27 and p53, release of cytochrome c and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem. 52:6330–6337. 2004. View Article : Google Scholar : PubMed/NCBI
23	Wu Z, Wu LJ, Li LH, Tashiro S, Onodera S and Ikejima T: Shikonin regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis. J Asian Nat Prod Res. 6:155–166. 2004. View Article : Google Scholar : PubMed/NCBI
24	Nakaya K and Miyasaka T: A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs. 14:683–693. 2003. View Article : Google Scholar : PubMed/NCBI
25	Roskoski R Jr: Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun. 331:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
26	Schlaepfer DD and Hunter T: Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol. 8:151–157. 1998. View Article : Google Scholar : PubMed/NCBI
27	Hanks SK, Calalb MB, Harper MC and Patel SK: Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci USA. 89:8487–8491. 1992. View Article : Google Scholar : PubMed/NCBI
28	Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB and Parsons JT: pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA. 89:5192–5196. 1992. View Article : Google Scholar : PubMed/NCBI
29	Calalb MB, Polte TR and Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol. 15:954–963. 1995.PubMed/NCBI
30	Cobb BS, Schaller MD, Leu TH and Parsons JT: Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. Mol Cell Biol. 14:147–155. 1994.PubMed/NCBI
31	Baron V, Calléja V, Ferrari P, Alengrin F and Van Obberghen E: p125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors. J Biol Chem. 273:7162–7168. 1998. View Article : Google Scholar : PubMed/NCBI
32	Schlaepfer DD, Hanks SK, Hunter T and van der Geer P: Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature. 372:786–791. 1994. View Article : Google Scholar : PubMed/NCBI
33	Recher C, Ysebaert L, Beyne-Rauzy O, et al: Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity and poor prognosis. Cancer Res. 64:3191–3197. 2004. View Article : Google Scholar : PubMed/NCBI